KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Net Margin (2016 - 2025)

Novavax has reported Net Margin over the past 16 years, most recently at 11.91% for Q4 2025.

  • Quarterly results put Net Margin at 11.91% for Q4 2025, up 10367.0% from a year ago — trailing twelve months through Dec 2025 was 41.57% (up 6905.0% YoY), and the annual figure for FY2025 was 39.19%, up 6668.0%.
  • Net Margin for Q4 2025 was 11.91% at Novavax, up from 287.29% in the prior quarter.
  • Over the last five years, Net Margin for NVAX hit a ceiling of 77.8% in Q1 2025 and a floor of 380.87% in Q4 2021.
  • Median Net Margin over the past 5 years was 65.58% (2023), compared with a mean of 100.97%.
  • Peak annual rise in Net Margin hit 71609bps in 2021, while the deepest fall reached -495844bps in 2021.
  • Novavax's Net Margin stood at 380.87% in 2021, then skyrocketed by 87bps to 50.99% in 2022, then decreased by -20bps to 61.23% in 2023, then plummeted by -50bps to 91.76% in 2024, then skyrocketed by 113bps to 11.91% in 2025.
  • The last three reported values for Net Margin were 11.91% (Q4 2025), 287.29% (Q3 2025), and 60.86% (Q2 2025) per Business Quant data.